The Mechanisms of Cancer Therapeutics-1 (MCT1) Study Section review applications addressing the mechanisms of action of anti-neoplastic agents including the effects of therapy on tumor cell growth, cell death, gene expression, and signaling networks, mechanisms of resistance to anti-neoplastic agents and therapeutic methods including resistance to conventional, targeted, and immunotherapy. The scope of projects includes evaluation of conventional, targeted and immunotherapeutic strategies in vitro, in preclinical animal models, and human tissues.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Mechanism(s) of action of anti-neoplastic agents or combinations of agents at the molecular, cellular, or target tissue level
- Mechanism(s) of resistance to anti-neoplastic agents and strategies for circumvention of resistance in vitro and in vivo
- Effect of anti-neoplastic agents on tumor cell anabolic processes including: macromolecular synthesis, DNA repair, gene regulation, immortalization, differentiation, cell cycle and checkpoint control, RNA translation, and signal transduction
- Effect of anti-neoplastic agents on tumor cell catabolic processes including: DNA damage, apoptotic and non-apoptotic cell death, protein degradation, protein stability, and stress-response pathways
- Combinations of targeted or conventional therapy with immunotherapy and studies with immunotherapy to circumvent chemo drug resistance
- Translation of discoveries in molecular biology to clinical intervention. Focus is on the translational setting using preclinical models and clinical samples in cancer drug discovery
Shared Interests and Overlaps
There are shared interests with Mechanisms of Cancer Therapeutics-1 (MCT2) in mechanism of action of cancer therapeutic agents. Applications focused on identification, and functional validation of molecular targets may be assigned to MCT2. Applications focused on mechanisms of resistance to anti-neoplastic agents and the mechanisms of action of anti-neoplastic agents or combinations of agents can be assigned to MCT1.
There are shared interests with Drug Discovery and Molecular Pharmacology (DMP) in developing conventional and molecularly targeted agents. Applications focused on early stages of drug discovery, synthesis, isolation and in vivo evaluation of new drugs or modification of existing compounds, could be assigned to DMP. Applications focused on mechanism of action at the molecular, cellular, or target tissue level may be assigned to MCT1.
There are shared interests with Radiation Therapeutics and Biology (RTB) in molecular and cellular mechanism of cancer therapy. Applications involving anti-neoplastic agents for tumor cell anabolic and catabolic processes may be assigned to MCT1. Studies focused on effects of radiation response may be assigned to RTB. Mechanistic studies using radiation along with other anti-neoplastic agents could be applied to either MCT1 or RTB depending on the emphasis of the studies.
There are shared interests with Developmental Therapeutics (DT) on therapeutic strategies involving combinations of cytotoxic drugs with targeting agents. Studies with advanced animal experiments and pilot clinical trials may be assigned to DT. Applications focused on mechanism of action of combination therapies and the effects of drug combination on anabolic and catabolic processes may be assigned to MCT1.
There are shared interesst with Cancer Immunopathology and Immunotherapy (CII) in treatments using conventional and/ or targeted agents combined with immunotherapy and in the use of immunotherapy to circumvent tumor resistance to conventional drug therapy. Applications that focus on both the immune-mediated and the drug-mediated mechanisms of the anti-tumor response may be appropriate for either CII or MCT1.
There are shared interests with Cancer Prevention Study Section (CPSS) in molecular mechanisms of cancer therapeutic agents. Studies focused on the mechanism of action of chemopreventive agents may be assigned to CPSS. Application focused on molecular mechanisms of cancer anti-neoplastic agents may be assigned to MCT1.
There are shared interests with Tumor Cell Biology Study Section (TCB) in regulation of tumor progression and signal transduction mechanisms in neoplastic cells. The analysis of signaling complexes and their interactions among different signaling pathways in the context of tumor biology and tumor progression may be assigned to TCB. Applications on the effects of anti-neoplastic agents on signaling pathways may be assigned to MCT1.
There are shared interests with Cancer Molecular Pathobiology Study Section (CAMP) in mechanisms controlling cell growth and death, and the molecular events in gene regulation. Basic studies of the biology of the malignant cell could be assigned to CAMP. Mechanistic studies on the effects of anti-neoplastic agents on regulation of cell growth and cell death, and gene expression may be assigned to MCT1.
There are shared interests with Molecular Oncogenesis Study Section (MONC) in cancer therapeutic agents. Applications that use anti-neoplastic agents as tools to examine transformation and early oncogenesis may be assigned to MONC. Applications that focus on the mechanisms of action of anti-neoplastic agents may be assigned to MCT1.
There are shared interests with
Clinical Neuroimmunology and Brain Tumors (CNBT) in the areas of mechanism and treatment of glioblastomas, medulloblastomas, neuroblastomas and gliomas. Applications that focus on the central nervous system consequences due to brain tumors may be assigned to CNBT. Applications that focus on Mechanism(s) of action of anti-neoplastic agents in brain tumors may be assigned to MCT1.